Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Pharmacol
2012 Nov 01;825:795-802. doi: 10.1124/mol.112.079194.
Show Gene links
Show Anatomy links
Structure-activity relationship of fenamates as Slo2.1 channel activators.
Garg P
,
Sanguinetti MC
.
???displayArticle.abstract???
Niflumic acid, 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid (NFA), a nonsteroidal anti-inflammatory drug that blocks cyclooxygenase (COX), was shown previously to activate [Na(+)](i)-regulated Slo2.1 channels. In this study, we report that other fenamates, including flufenamic acid, mefenamic acid, tolfenamic acid, meclofenamic acid, and a phenyl acetic acid derivative, diclofenac, also are low-potency (EC(50) = 80 μM to 2.1 mM), partial agonists of human Slo2.1 channels heterologously expressed in Xenopus oocytes. Substituent analysis determined that N-phenylanthranilic acid was the minimal pharmacophore for fenamate activation of Slo2.1 channels. The effects of fenamates were biphasic, with an initial rapid activation phase followed by a slow phase of current inhibition. Ibuprofen, a structurally dissimilar COX inhibitor, did not activate Slo2.1. Preincubation of oocytes with ibuprofen did not significantly alter the effects of NFA, suggesting that neither channel activation nor inhibition is associated with COX activity. A point mutation (A278R) in the pore-lining S6 segment of Slo2.1 increased the sensitivity to activation and reduced the inhibition induced by NFA. Together, our results suggest that fenamates bind to two sites on Slo2.1 channels: an extracellular accessible site to activate and a cytoplasmic accessible site in the pore to inhibit currents.
Barnett,
Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system.
1994, Pubmed
Barnett,
Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system.
1994,
Pubmed
Bhattacharjee,
Slick (Slo2.1), a rapidly-gating sodium-activated potassium channel inhibited by ATP.
2003,
Pubmed
,
Xenbase
Busch,
Positive regulation by chloride channel blockers of IsK channels expressed in Xenopus oocytes.
1994,
Pubmed
,
Xenbase
Dai,
Activation of Slo2.1 channels by niflumic acid.
2010,
Pubmed
,
Xenbase
Dhanaraj,
Structural studies of analgesics and their interactions. XII. Structure and interactions of anti-inflammatory fenamates. A concerted crystallographic and theoretical conformational study.
1988,
Pubmed
Farrugia,
Potassium current in circular smooth muscle of human jejunum activated by fenamates.
1993,
Pubmed
Fernandez,
Structural basis for ether-a-go-go-related gene K+ channel subtype-dependent activation by niflumic acid.
2008,
Pubmed
,
Xenbase
Flower,
Effects of anti-inflammatory drugs on prostaglandin biosynthesis.
1972,
Pubmed
Gögelein,
Flufenamic acid, mefenamic acid and niflumic acid inhibit single nonselective cation channels in the rat exocrine pancreas.
1990,
Pubmed
Greenwood,
Comparison of the effects of fenamates on Ca-activated chloride and potassium currents in rabbit portal vein smooth muscle cells.
1995,
Pubmed
Gribkoff,
Effects of channel modulators on cloned large-conductance calcium-activated potassium channels.
1996,
Pubmed
,
Xenbase
Grover,
The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.
1994,
Pubmed
Hu,
Activation of TRPA1 channels by fenamate nonsteroidal anti-inflammatory drugs.
2010,
Pubmed
,
Xenbase
Jiang,
Effect of non-steroidal anti-inflammatory drugs and new fenamate analogues on TRPC4 and TRPC5 channels.
2012,
Pubmed
Kameyama,
Intracellular Na+ activates a K+ channel in mammalian cardiac cells.
,
Pubmed
Liantonio,
Activation and inhibition of kidney CLC-K chloride channels by fenamates.
2006,
Pubmed
,
Xenbase
Liantonio,
Molecular switch for CLC-K Cl- channel block/activation: optimal pharmacophoric requirements towards high-affinity ligands.
2008,
Pubmed
,
Xenbase
Malykhina,
Fenamate-induced enhancement of heterologously expressed HERG currents in Xenopus oocytes.
2002,
Pubmed
,
Xenbase
Ottolia,
Potentiation of large conductance KCa channels by niflumic, flufenamic, and mefenamic acids.
1994,
Pubmed
Peretz,
Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.
2005,
Pubmed
Sanger,
Fenamates may antagonize the actions of prostaglandin endoperoxides in human myometrium.
1979,
Pubmed
Santi,
Opposite regulation of Slick and Slack K+ channels by neuromodulators.
2006,
Pubmed
,
Xenbase
Schreibmayer,
Voltage clamping of Xenopus laevis oocytes utilizing agarose-cushion electrodes.
1994,
Pubmed
,
Xenbase
Stühmer,
Electrophysiological recording from Xenopus oocytes.
1992,
Pubmed
,
Xenbase
Wang,
Unexpected and differential effects of Cl- channel blockers on the Kv4.3 and Kv4.2 K+ channels. Implications for the study of the I(to2) current.
1997,
Pubmed
,
Xenbase
Wang,
Conductance properties of the Na(+)-activated K+ channel in guinea-pig ventricular cells.
1991,
Pubmed
White,
Niflumic and flufenamic acids are potent reversible blockers of Ca2(+)-activated Cl- channels in Xenopus oocytes.
1990,
Pubmed
,
Xenbase
Wiemuth,
The pharmacological profile of brain liver intestine Na+ channel: inhibition by diarylamidines and activation by fenamates.
2011,
Pubmed
,
Xenbase
Yuan,
The sodium-activated potassium channel is encoded by a member of the Slo gene family.
2003,
Pubmed
,
Xenbase
